3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
685
Breast Neoplasms
584
Neoplasms
468
Colorectal Neoplasms
298
Prostatic Neoplasms
262
Neoplasm Metastasis
256
Melanoma
241
Ovarian Neoplasms
228
Recurrence
216
Lung Neoplasms
203
Multiple Myeloma
195
Lymphoma, Non-Hodgkin
155
Pancreatic Neoplasms
154
Leukemia, Myeloid, Acute
141
Carcinoma, Hepatocellular
141
Stomach Neoplasms
137
Lymphoma
131
Carcinoma, Renal Cell
128
Glioblastoma
118
Head and Neck Neoplasms
112
Squamous Cell Carcinoma of Head and Neck
111
Lymphoma, Follicular
106
Leukemia, Lymphocytic, Chronic, B-Cell
99
Lymphoma, Large B-Cell, Diffuse
96
Leukemia
96
Small Cell Lung Carcinoma
95
Brain Neoplasms
91
Carcinoma
82
Uterine Cervical Neoplasms
76
Triple Negative Breast Neoplasms
72
Interventions
enzalutamide
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
INDUSTRY
×
Biochemically Recurrent Prostate Cancer
×
Clear all
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts